Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Sahlgrenska Anti-VEGF Study
Sponsor: Vastra Gotaland Region
Summary
The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.
Official title: The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
402
Start Date
2020-09-03
Completion Date
2027-05
Last Updated
2025-11-21
Healthy Volunteers
No
Interventions
Bevacizumab Injection
25 mg/ml
Aflibercept Injection
40 mg/ml
Locations (1)
Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology
Mölndal, Sweden